Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: A feasibility study

Radiotherapy and Oncology

Volumn 87, Issue 1, 2008, Pages 55-58

  van Baardwijk, Angela ^a   Bosmans, Geert ^a   van Suylen, Robert Jan ^a   van Kroonenburgh, Marinus ^a   Hochstenbag, Monique ^a   Geskes, Gijs ^a   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG PET; Ex vivo model; Intra tumour heterogeneity; NSCLC; Pathology

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG UPTAKE; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE SECTION;

ADULT; AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 41849091443     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.02.002     Document Type: Article

References (18)

1. Stroobants S., Verschakelen J., and Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol 45 (2003) 49-59
2. van Baardwijk A., Baumert B.G., Bosmans G., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
3. Nestle U., Kremp S., and Grosu A.L. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81 (2006) 209-225
4. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
5. Mamede M., Higashi T., Kitaichi M., et al. [18F]-FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7 (2005) 369-379
6. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., and Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]-fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 683-691
7. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
8. Dearling J.L., Flynn A.A., Sutcliffe-Goulden J., et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 45 (2004) 101-107
9. Zhao S., Kuge Y., Mochizuki T., et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46 (2005) 675-682
10. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., and Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 25 (1998) 317-322
11. International Commission on Radiological Protection. Radiation dose to Patients from Radiopharmaceuticals, Publication 80. Oxford: Pergamon Press; 1999.
12. Chan R., He Y., Haque A., and Zwischenberger J. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. Arch Pathol Lab Med 125 (2001) 1469-1472
13. Grills I.S., Fitch D.L., Goldstein N.S., et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys (2007)
14. Giraud P., Antoine M., Larrouy A., et al. Evaluation of microscopic tumor extension in non-small cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48 (2000) 1015-1024
15. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., and Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [(18)F]-fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 683-691
16. Sorensen M., Horsman M.R., Cumming P., Munk O.L., and Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 62 (2005) 854-861
17. Pugachev A., Ruan S., Carlin S., et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62 (2005) 545-553
18. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-1227